Rhenman & Partners Asset Management AB
13F Reported Value
ⓘ$1.1B
Holdings
99
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Rhenman & Partners Asset Management AB disclosed 99 positions worth $1.1B in its Form 13F-HR for Q2 2026, led by $UNH (UNITEDHEALTH GROUP INC) at 3.7% of the equity portfolio, followed by $CVS and $AZN. During the quarter the fund opened 20 new positions and exited 7 — including a new stake in $AZN and a full exit from $ADPT. The portfolio is most concentrated in Healthcare (91.4% of disclosed assets). All figures are sourced directly from Rhenman & Partners Asset Management AB’s Form 13F-HR filing with the SEC under CIK 1599882.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 62.7#687
Quality
$38.9M93,600 sh - 59.4#928
Quality
$28.9M279,374 sh - —
Quality
$28.5M151,500 sh - 59.9
Quality
$27.4M213,500 sh - 87.5
Quality
$26.8M22,315 sh - 72.6
Quality
$24.4M96,775 sh - 64.2
Quality
$23.7M997,083 sh - 69.4
Quality
$23.5M260,000 sh - 57.4
Quality
$22.5M178,250 sh - —
Quality
$21.1M87,440 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 UNITEDHEALTH GROUP INC$UNH | 62.7#687 | $38.9M | 93,600 |
 CVS HEALTH Corp$CVS | 59.4#928 | $28.9M | 279,374 |
 ASTRAZENECA PLC$AZN | — | $28.5M | 151,500 |
 Merck & Co., Inc.$MRK | 59.9 | $27.4M | 213,500 |
 ELI LILLY & Co$LLY | 87.5 | $26.8M | 22,315 |
 AbbVie Inc.$ABBV | 72.6 | $24.4M | 96,775 |
 Alignment Healthcare, Inc.$ALHC | 64.2 | $23.7M | 997,083 |
 Edwards Lifesciences Corp$EW | 69.4 | $23.5M | 260,000 |
 GILEAD SCIENCES, INC.$GILD | 57.4 | $22.5M | 178,250 |
 Jazz Pharmaceuticals plc$JAZZ | — | $21.1M | 87,440 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Rhenman & Partners Asset Management AB's 99 positions.
Showing top 10 of 99 holdings.
Sector Allocation
Healthcare
$968.4M
Technology
$55.2M
Consumer Staples
$31.1M
Industrials
$4.7M
Full Holdings — Rhenman & Partners Asset Management AB (Q2 2026)
All 99 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $UNH | UNITEDHEALTH GROUP INC | $38.9M | 3.7% | +106% | 62.7 |
| 2 | $CVS | CVS HEALTH Corp | $28.9M | 2.7% | -17% | 59.4 |
| 3 | $AZN | ASTRAZENECA PLC | $28.5M | 2.7% | NEW | — |
| 4 | $MRK | Merck & Co., Inc. | $27.4M | 2.6% | NEW | 59.9 |
| 5 | $LLY | ELI LILLY & Co | $26.8M | 2.5% | -34% | 87.5 |
| 6 | $ABBV | AbbVie Inc. | $24.4M | 2.3% | +35% | 72.6 |
| 7 | $ALHC | Alignment Healthcare, Inc. | $23.7M | 2.2% | -5% | 64.2 |
| 8 | $EW | Edwards Lifesciences Corp | $23.5M | 2.2% | +60% | 69.4 |
| 9 | $GILD | GILEAD SCIENCES, INC. | $22.5M | 2.1% | +6% | 57.4 |
| 10 | $JAZZ | Jazz Pharmaceuticals plc | $21.1M | 2.0% | +15% | — |
| 11 |  $BIIB | BIOGEN INC. | $20.5M | 1.9% | -13% | 64.7 |
| 12 |  $SYK | STRYKER CORP | $20.5M | 1.9% | +36% | 72.1 |
| 13 |  $BSX | BOSTON SCIENTIFIC CORP | $19.2M | 1.8% | -28% | 77.5 |
| 14 |  $JNJ | JOHNSON & JOHNSON | $18.4M | 1.7% | NEW | 69 |
| 15 |  $GH | Guardant Health, Inc. | $17.3M | 1.6% | -21% | 39 |
| 16 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $17.1M | 1.6% | -43% | 71 |
| 17 |  $GKOS | GLAUKOS Corp | $16.6M | 1.6% | +42% | 40.5 |
| 18 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $16.6M | 1.6% | +40% | 58.2 |
| 19 |  $NRIX | Nurix Therapeutics, Inc. | $16.6M | 1.6% | +118% | 6.4 |
| 20 |  $NTRA | Natera, Inc. | $16.6M | 1.6% | +18% | 53.5 |
| 21 |  $MIRM | Mirum Pharmaceuticals, Inc. | $16.3M | 1.5% | +50% | 35 |
| 22 |  $INSM | INSMED Inc | $16.2M | 1.5% | -5% | 39.4 |
| 23 |  $THC | TENET HEALTHCARE CORP | $15.9M | 1.5% | +58% | 66.2 |
| 24 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $15.8M | 1.5% | -24% | 65.1 |
| 25 |  $CNC | CENTENE CORP | $15.7M | 1.5% | NEW | 58.2 |
| 26 |  $AXSM | Axsome Therapeutics, Inc. | $15.4M | 1.5% | -1% | 40.8 |
| 27 |  $DHR | DANAHER CORP /DE/ | $15.3M | 1.4% | +345% | 64.8 |
| 28 |  $VRTX | VERTEX PHARMACEUTICALS INC / MA | $15.2M | 1.4% | -29% | 75.4 |
| 29 |  $AVR | Anteris Technologies Global Corp. | $15.2M | 1.4% | +7% | — |
| 30 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $14.5M | 1.4% | -15% | 76.5 |
| 31 |  $PNTG | Pennant Group, Inc. | $13.7M | 1.3% | +35% | 62.6 |
| 32 |  $ISRG | INTUITIVE SURGICAL INC | $13.7M | 1.3% | -6% | 79.9 |
| 33 |  $ELV | Elevance Health, Inc. | $13.5M | 1.3% | +8% | 59 |
| 34 |  $LIVN | LivaNova PLC | $13.5M | 1.3% | +6% | — |
| 35 |  $COR | Cencora, Inc. | $13.2M | 1.3% | -11% | 61.1 |
| 36 |  $CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $13.0M | 1.2% | +120% | 43.8 |
| 37 |  $IDYA | IDEAYA Biosciences, Inc. | $12.8M | 1.2% | +35% | 36.1 |
| 38 |  $MCK | MCKESSON CORP | $12.5M | 1.2% | -2% | 63.4 |
| 39 |  $SNDX | Syndax Pharmaceuticals Inc | $12.2M | 1.2% | +48% | 33.8 |
| 40 |  $BTSG | BrightSpring Health Services, Inc. | $11.6M | 1.1% | +232% | 63.3 |
| 41 |  $MDT | Medtronic plc | $11.3M | 1.1% | +61% | 68.7 |
| 42 |  $MLYS | Mineralys Therapeutics, Inc. | $11.2M | 1.1% | +58% | — |
| 43 |  $OSCR | Oscar Health, Inc. | $11.2M | 1.1% | -41% | 83.1 |
| 44 |  $RPRX | Royalty Pharma plc | $11.0M | 1.0% | -15% | — |
| 45 |  $DXCM | DEXCOM INC | $10.8M | 1.0% | NEW | 76 |
| 46 |  $ALGN | ALIGN TECHNOLOGY INC | $10.6M | 1.0% | +740% | 58.9 |
| 47 |  $SYRE | Spyre Therapeutics, Inc. | $10.6M | 1.0% | NEW | — |
| 48 |  $RLAY | Relay Therapeutics, Inc. | $10.6M | 1.0% | +57% | 19.5 |
| 49 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $10.4M | 1.0% | -11% | 38.7 |
| 50 |  $A | AGILENT TECHNOLOGIES, INC. | $10.0M | 0.9% | +200% | 67.1 |
| 51 |  $NKTR | NEKTAR THERAPEUTICS | $9.9M | 0.9% | +139% | 9.7 |
| 52 |  $ALKS | Alkermes plc. | $9.7M | 0.9% | +39% | — |
| 53 |  $ABT | ABBOTT LABORATORIES | $8.7M | 0.8% | -14% | 65.5 |
| 54 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $8.4M | 0.8% | +6% | 22.6 |
| 55 |  $PRCT | PROCEPT BioRobotics Corp | $7.8M | 0.7% | -27% | 33.3 |
| 56 |  $GPCR | Structure Therapeutics Inc. | $7.8M | 0.7% | +13% | — |
| 57 |  $ORKA | Oruka Therapeutics, Inc. | $7.6M | 0.7% | NEW | — |
| 58 |  $EHC | Encompass Health Corp | $7.5M | 0.7% | +32% | 66.9 |
| 59 |  $MLTX | MoonLake Immunotherapeutics | $7.5M | 0.7% | +61% | — |
| 60 |  $IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $7.1M | 0.7% | -17% | 36.8 |
| 61 |  $BBIO | BridgeBio Pharma, Inc. | $6.8M | 0.6% | +1% | 36.9 |
| 62 |  $KURA | Kura Oncology, Inc. | $6.5M | 0.6% | +118% | 27.6 |
| 63 |  $PODD | INSULET CORP | $6.4M | 0.6% | +200% | 71.3 |
| 64 |  $ERAS | Erasca, Inc. | $6.4M | 0.6% | NEW | — |
| 65 |  $KRYS | Krystal Biotech, Inc. | $6.1M | 0.6% | -2% | 79.2 |
| 66 |  $STVN | Stevanato Group S.p.A. | $5.5M | 0.5% | +11% | — |
| 67 |  $ASTH | Astrana Health, Inc. | $5.5M | 0.5% | NEW | 60.7 |
| 68 |  $CAH | CARDINAL HEALTH INC | $5.3M | 0.5% | -17% | 62.4 |
| 69 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $5.2M | 0.5% | -50% | 71.4 |
| 70 |  $MOH | MOLINA HEALTHCARE, INC. | $5.0M | 0.5% | NEW | 56.5 |
| 71 |  $VKTX | Viking Therapeutics, Inc. | $5.0M | 0.5% | -20% | — |
| 72 |  $CI | Cigna Group | $4.8M | 0.5% | +118% | 66.2 |
| 73 |  $IONS | IONIS PHARMACEUTICALS INC | $4.7M | 0.5% | -36% | 23.4 |
| 74 |  $AMN | AMN HEALTHCARE SERVICES INC | $4.7M | 0.4% | NEW | 54.5 |
| 75 |  $DNLI | Denali Therapeutics Inc. | $4.6M | 0.4% | -10% | — |
| 76 |  $MEDP | Medpace Holdings, Inc. | $4.5M | 0.4% | NEW | 76.2 |
| 77 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $4.3M | 0.4% | -67% | 40.7 |
| 78 |  $AMGN | AMGEN INC | $4.3M | 0.4% | -22% | 79.2 |
| 79 |  $SION | Sionna Therapeutics, Inc. | $4.3M | 0.4% | +11% | — |
| 80 |  $ASND | Ascendis Pharma A/S | $4.0M | 0.4% | +0% | 44.8 |
| 81 |  $COO | COOPER COMPANIES, INC. | $3.9M | 0.4% | +8% | 57 |
| 82 |  $WAY | Waystar Holding Corp. | $3.7M | 0.3% | -48% | 65.5 |
| 83 |  $MBX | MBX Biosciences, Inc. | $3.4M | 0.3% | NEW | — |
| 84 |  $VCEL | Vericel Corp | $3.1M | 0.3% | +0% | 62.8 |
| 85 |  $VEEV | VEEVA SYSTEMS INC | $3.1M | 0.3% | -80% | 77.6 |
| 86 |  $BCAX | Bicara Therapeutics Inc. | $2.6M | 0.3% | NEW | — |
| 87 |  $STE | STERIS plc | $2.4M | 0.2% | +0% | — |
| 88 |  $OCUL | OCULAR THERAPEUTIX, INC | $2.2M | 0.2% | -26% | 8.4 |
| 89 |  $STOK | Stoke Therapeutics, Inc. | $2.1M | 0.2% | -22% | 24.9 |
| 90 |  $XENE | Xenon Pharmaceuticals Inc. | $2.0M | 0.2% | +19% | 24 |
| 91 |  $DOCS | Doximity, Inc. | $1.6M | 0.1% | -59% | 68.5 |
| 92 |  $PRVA | Privia Health Group, Inc. | $1.3M | 0.1% | NEW | 60.1 |
| 93 |  $NVCR | NovoCure Ltd | $1.1M | 0.1% | +0% | — |
| 94 |  $MMED | MiniMed Group, Inc. | $822,250 | 0.1% | NEW | 44.2 |
| 95 |  $ATEC | Alphatec Holdings, Inc. | $735,250 | 0.1% | +21% | 43.3 |
| 96 |  $AGL | agilon health, inc. | $535,900 | 0.1% | NEW | 44.9 |
| 97 |  $TXG | 10x Genomics, Inc. | $325,890 | 0.0% | NEW | 40.5 |
| 98 |  $TNDM | TANDEM DIABETES CARE INC | $301,800 | 0.0% | NEW | 42.8 |
| 99 |  $TGTX | TG THERAPEUTICS, INC. | $274,700 | 0.0% | NEW | 69.3 |
New Positions (20)
$AZN ASTRAZENECA PLC$28.5M$MRK Merck & Co., Inc.$27.4M$JNJ JOHNSON & JOHNSON$18.4M$CNC CENTENE CORP$15.7M$DXCM DEXCOM INC$10.8M$SYRE Spyre Therapeutics, Inc.$10.6M$ORKA Oruka Therapeutics, Inc.$7.6M$ERAS Erasca, Inc.$6.4M$ASTH Astrana Health, Inc.$5.5M$MOH MOLINA HEALTHCARE, INC.$5.0M$AMN AMN HEALTHCARE SERVICES INC$4.7M$MEDP Medpace Holdings, Inc.$4.5M$MBX MBX Biosciences, Inc.$3.4M$BCAX Bicara Therapeutics Inc.$2.6M$PRVA Privia Health Group, Inc.$1.3M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Rhenman & Partners Asset Management AB including:
Track Rhenman & Partners Asset Management AB's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Rhenman & Partners Asset Management AB and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Rhenman & Partners Asset Management AB
13F Pro is an AI hedge fund tracker and stock research platform. For Rhenman & Partners Asset Management AB (SEC CIK: 1599882), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Rhenman & Partners Asset Management AB's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.